Current challenges towards the development of a blood test for Parkinson's disease

Diagnostics

Volumn 4, Issue 4, 2014, Pages 153-164

  Santiago, Jose A ^a   Potashkin, Judith A ^a  

^a ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

Biomarkers; Blood; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BIOLOGICAL MARKER; DJ 1 PROTEIN; LEUCINE RICH REPEAT KINASE 2; MESSENGER RNA; PROTEIN SNCA; PROTEIN TYROSINE PHOSPHATASE 1B; RNA; UNCLASSIFIED DRUG;

APP GENE; BLOOD ANALYSIS; DIAGNOSTIC TEST; DJ 1 GENE; GENE; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; HUMAN; LRRK2 GENE; MICROARRAY ANALYSIS; PARKINSON DISEASE; PTPN1 GENE; REVIEW; RISK FACTOR; SNCA GENE; SOD2 GENE;

EID: 84955566351     PISSN: None     EISSN: 20754418     Source Type: Journal    
DOI: 10.3390/diagnostics4040153     Document Type: Review

References (58)

1. Pringsheim, T.; Jette, N.; Frolkis, A.; Steeves, T.D. The prevalence of parkinson's disease: A systematic review and meta-analysis. Mov. Disord. 2014, doi:10.1002/mds.25945.
2. Luk, K.C.; Kehm, V.; Carroll, J.; Zhang, B.; O'Brien, P.; Trojanowski, J.Q.; Lee, V.M. Pathological alpha-synuclein transmission initiates parkinson-like neurodegeneration in nontransgenic mice. Science 2012, 338, 949-953.
3. Olanow, C.W.; Brundin, P. Parkinson's disease and alpha synuclein: Is parkinson's disease a prion-like disorder? Mov. Disord. 2013, 28, 31-40.
4. Schapira, A.H.; Olanow, C.W.; Greenamyre, J.T.; Bezard, E. Slowing of neurodegeneration in parkinson's disease and huntington's disease: Future therapeutic perspectives. Lancet 2014, 384, 545-555.
5. Lin, M.K.; Farrer, M.J. Genetics and genomics of parkinson's disease. Genome Med. 2014, 6, 48.
6. Miller, D.W.; Hague, S.M.; Clarimon, J.; Baptista, M.; Gwinn-Hardy, K.; Cookson, M.R.; Singleton, A.B. Alpha-synuclein in blood and brain from familial parkinson disease with snca locus triplication. Neurology 2004, 62, 1835-1838.
7. Foulds, P.G.; Diggle, P.; Mitchell, J.D.; Parker, A.; Hasegawa, M.; Masuda-Suzukake, M.; Mann, D.M.; Allsop, D. A longitudinal study on alpha-synuclein in blood plasma as a biomarker for parkinson's disease. Sci. Rep. 2013, 3, 2540.
8. Foulds, P.G.; Mitchell, J.D.; Parker, A.; Turner, R.; Green, G.; Diggle, P.; Hasegawa, M.; Taylor, M.; Mann, D.; Allsop, D. Phosphorylated alpha-synuclein can be detected in blood plasma and is potentially a useful biomarker for parkinson's disease. FASEB J. 2011, 25, 4127-4137.
9. Besong-Agbo, D.; Wolf, E.; Jessen, F.; Oechsner, M.; Hametner, E.; Poewe, W.; Reindl, M.; Oertel, W.H.; Noelker, C.; Bacher, M.; et al. Naturally occurring alpha-synuclein autoantibody levels are lower in patients with parkinson disease. Neurology 2013, 80, 169-175.
10. Bonifati, V.; Rizzu, P.; van Baren, M.J.; Schaap, O.; Breedveld, G.J.; Krieger, E.; Dekker, M.C.; Squitieri, F.; Ibanez, P.; Joosse, M.; et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003, 299, 256-259.
11. Taira, T.; Saito, Y.; Niki, T.; Iguchi-Ariga, S.M.; Takahashi, K.; Ariga, H. DJ-1 has a role in antioxidative stress to prevent cell death. EMBO Rep. 2004, 5, 213-218.
12. Lin, X.; Cook, T.J.; Zabetian, C.P.; Leverenz, J.B.; Peskind, E.R.; Hu, S.C.; Cain, K.C.; Pan, C.; Edgar, J.S.; Goodlett, D.R.; et al. DJ-1 isoforms in whole blood as potential biomarkers of parkinson disease. Sci. Rep. 2012, 2, 954.
13. Dzamko, N.; Chua, G.; Ranola, M.; Rowe, D.B.; Halliday, G.M. Measurement of LRRK2 and ser910/935 phosphorylated LRRK2 in peripheral blood mononuclear cells from idiopathic parkinson's disease patients. J. Parkinsons Dis. 2013, 3, 145-152.
14. Han, M.; Nagele, E.; DeMarshall, C.; Acharya, N.; Nagele, R. Diagnosis of parkinson's disease based on disease-specific autoantibody profiles in human sera. PLoS One 2012, 7, e32383.
15. Ding, H.; Dhima, K.; Lockhart, K.C.; Locascio, J.J.; Hoesing, A.N.; Duong, K.; Trisini-Lipsanopoulos, A.; Hayes, M.T.; Sohur, U.S.; Wills, A.M.; et al. Unrecognized vitamin D3 deficiency is common in parkinson disease: Harvard biomarker study. Neurology 2013, 81, 1531-1537.
16. Sato, Y.; Kikuyama, M.; Oizumi, K. High prevalence of vitamin d deficiency and reduced bone mass in parkinson's disease. Neurology 1997, 49, 1273-1278.
17. Korff, A.; Pfeiffer, B.; Smeyne, M.; Kocak, M.; Pfeiffer, R.F.; Smeyne, R.J. Alterations in glutathione S-transferase pi expression following exposure to mpp+ -induced oxidative stress in the blood of parkinson's disease patients. Parkinsonism Relat. Disord. 2011, 17, 765-768.
18. Nolan, Y.M.; Sullivan, A.M.; Toulouse, A. Parkinson's disease in the nuclear age of neuroinflammation. Trends Mol. Med. 2013, 19, 187-196.
19. Spielman, L.J.; Little, J.P.; Klegeris, A. Inflammation and insulin/IGF-1 resistance as the possible link between obesity and neurodegeneration. J. Neuroimmunol. 2014, 273, 8-21.
20. Baba, Y.; Kuroiwa, A.; Uitti, R.J.; Wszolek, Z.K.; Yamada, T. Alterations of T-lymphocyte populations in parkinson disease. Parkinsonism Relat. Disord. 2005, 11, 493-498.
21. Scherzer, C.R.; Eklund, A.C.; Morse, L.J.; Liao, Z.; Locascio, J.J.; Fefer, D.; Schwarzschild, M.A.; Schlossmacher, M.G.; Hauser, M.A.; Vance, J.M.; et al. Molecular markers of early parkinson's disease based on gene expression in blood. Proc. Natl. Acad. Sci. USA 2007, 104, 955-960.
22. Zheng, B.; Liao, Z.; Locascio, J.J.; Lesniak, K.A.; Roderick, S.S.; Watt, M.L.; Eklund, A.C.; Zhang-James, Y.; Kim, P.D.; Hauser, M.A.; et al. Pgc-1alpha, a potential therapeutic target for early intervention in parkinson's disease. Sci. Transl. Med. 2010, 2, 52ra73.
23. Molochnikov, L.; Rabey, J.M.; Dobronevsky, E.; Bonucelli, U.; Ceravolo, R.; Frosini, D.; Grunblatt, E.; Riederer, P.; Jacob, C.; Aharon-Peretz, J.; et al. A molecular signature in blood identifies early parkinson's disease. Mol. Neurodegener. 2012, 7, 26.
24. Karlsson, M.K.; Sharma, P.; Aasly, J.; Toft, M.; Skogar, O.; Saebo, S.; Lonneborg, A. Found in transcription: Accurate parkinson's disease classification in peripheral blood. J. Parkinsons Dis. 2013, 3, 19-29.
25. Wang, E.T.; Sandberg, R.; Luo, S.; Khrebtukova, I.; Zhang, L.; Mayr, C.; Kingsmore, S.F.; Schroth, G.P.; Burge, C.B. Alternative isoform regulation in human tissue transcriptomes. Nature 2008, 456, 470-476.
26. Shehadeh, L.A.; Yu, K.; Wang, L.; Guevara, A.; Singer, C.; Vance, J.; Papapetropoulos, S. SRRM2, a potential blood biomarker revealing high alternative splicing in parkinson's disease. PLoS One 2010, 5, e9104.
27. Potashkin, J.A.; Santiago, J.A.; Ravina, B.M.; Watts, A.; Leontovich, A.A. Biosignatures for parkinson's disease and atypical parkinsonian disorders patients. PLoS One 2012, 7, e43595.
28. Santiago, J.A.; Scherzer, C.R.; Potashkin, J.A. Specific splice variants are associated with parkinson's disease. Mov. Disord. 2013, 28, 1724-1727.
29. Soreq, L.; Bergman, H.; Israel, Z.; Soreq, H. Exon arrays reveal alternative splicing aberrations in parkinson's disease leukocytes. Neurodegener. Dis. 2012, 10, 203-206.
30. Soreq, L.; Guffanti, A.; Salomonis, N.; Simchovitz, A.; Israel, Z.; Bergman, H.; Soreq, H. Long non-coding rna and alternative splicing modulations in parkinson's leukocytes identified by RNA sequencing. PLoS Comput. Biol. 2014, 10, e1003517.
31. Santiago, J.A.; Potashkin, J.A. A network approach to clinical intervention in neurodegenerative diseases. Trends Mol. Med. 2014, in press.
32. Santiago, J.A.; Potashkin, J.A. A network approach to diagnostic biomarkers in progressive supranuclear palsy. Mov. Disord. 2014, 29, 550-555.
33. Hu, G.; Jousilahti, P.; Bidel, S.; Antikainen, R.; Tuomilehto, J. Type 2 diabetes and the risk of parkinson's disease. Diabetes Care 2007, 30, 842-847.
34. Xu, Q.; Park, Y.; Huang, X.; Hollenbeck, A.; Blair, A.; Schatzkin, A.; Chen, H. Diabetes and risk of parkinson's disease. Diabetes Care 2011, 34, 910-915.
35. Cereda, E.; Barichella, M.; Cassani, E.; Caccialanza, R.; Pezzoli, G. Clinical features of parkinson disease when onset of diabetes came first: A case-control study. Neurology 2012, 78, 1507-1511.
36. Cereda, E.; Barichella, M.; Pedrolli, C.; Klersy, C.; Cassani, E.; Caccialanza, R.; Pezzoli, G. Diabetes and risk of parkinson's disease: A systematic review and meta-analysis. Diabetes Care 2011, 34, 2614-2623.
37. Sun, Y.; Chang, Y.H.; Chen, H.F.; Su, Y.H.; Su, H.F.; Li, C.Y. Risk of parkinson disease onset in patients with diabetes: A 9-year population-based cohort study with age and sex stratifications. Diabetes Care 2012, 35, 1047-1049.
38. Santiago, J.A.; Potashkin, J.A. Shared dysregulated pathways lead to parkinson's disease and diabetes. Trends Mol. Med. 2013, 19, 176-186.
39. Aviles-Olmos, I.; Limousin, P.; Lees, A.; Foltynie, T. Parkinson's disease, insulin resistance and novel agents of neuroprotection. Brain 2013, 136, 374-384.
40. Santiago, J.A.; Potashkin, J.A. System-based approaches to decode the molecular links in parkinson's disease and diabetes. Neurobiol Dis 2014, in press.
41. Santiago, J.A.; Potashkin, J.A. Integrative network analysis unveils convergent molecular pathways in parkinson's disease and diabetes. PLoS One 2013, 8, e83940.
42. Masliah, E.; Rockenstein, E.; Veinbergs, I.; Sagara, Y.; Mallory, M.; Hashimoto, M.; Mucke, L. Beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking alzheimer's disease and parkinson's disease. Proc. Natl. Acad. Sci. USA 2001, 98, 12245-12250.
43. Alves, G.; Pedersen, K.F.; Bloem, B.R.; Blennow, K.; Zetterberg, H.; Borm, G.F.; Dalaker, T.O.; Beyer, M.K.; Aarsland, D.; Andreasson, U.; et al. Cerebrospinal fluid amyloid-beta and phenotypic heterogeneity in de novo parkinson's disease. J. Neurol. Neurosurg. Psychiatry 2013, 84, 537-543.
44. Santiago, J.A.; Scherzer, C.R.; Potashkin, J.A. Network analysis identifies SOD2 mRNA as a potential biomarker for parkinson's disease. PLoS One 2014, 9, e109042.
45. Kotagal, V.; Albin, R.L.; Muller, M.L.; Koeppe, R.A.; Frey, K.A.; Bohnen, N.I. Diabetes is associated with postural instability and gait difficulty in parkinson disease. Parkinsonism Relat. Disord. 2013, 19, 522-526.
46. Hennecke, G.; Scherzer, C.R. RNA biomarkers of parkinson's disease: Developing tools for novel therapies. Biomark. Med. 2008, 2, 41-53.
47. Ding, H.; Sarokhan, A.K.; Roderick, S.S.; Bakshi, R.; Maher, N.E.; Ashourian, P.; Kan, C.G.; Chang, S.; Santarlasci, A.; Swords, K.E.; et al. Association of snca with parkinson: Replication in the harvard neurodiscovery center biomarker study. Mov. Disord. 2011, 26, 2283-2286.
48. Harvard neurodiscovery center. Available online: http://www.neurodiscovery.harvard.edu/ research/biomarkers.html (accessed on 9 September 2014).
49. Mehanna, R.; Scherzer, C.R.; Ding, H.; Locascio, J.J. Unrecognized vitamin D3 deficiency is common in parkinson disease: Harvard biomarker study. Neurology 2014, 82, 1666; discussion 1666.
50. The parkinson progression marker initiative (ppmi). Prog. Neurobiol. 2011, 95, 629-635.
51. Parkinson's progression markers initiative. Available online: http://www.ppmi-info.org/ (accessed on 9 September 2014)
52. Siderowf, A.; Jennings, D.; Eberly, S.; Oakes, D.; Hawkins, K.A.; Ascherio, A.; Stern, M.B.; Marek, K. Impaired olfaction and other prodromal features in the parkinson at-risk syndrome study. Mov. Disord. 2012, 27, 406-412.
53. Berg, D.; Marek, K.; Ross, G.W.; Poewe, W. Defining at-risk populations for parkinson's disease: Lessons from ongoing studies. Mov. Disord. 2012, 27, 656-665.
54. Parkinson's associated risk study. Available online: http://www.parsinfosource.com/ (accessed on 9 September 2014).
55. Aviles-Olmos, I.; Dickson, J.; Kefalopoulou, Z.; Djamshidian, A.; Ell, P.; Soderlund, T.; Whitton, P.; Wyse, R.; Isaacs, T.; Lees, A.; et al. Exenatide and the treatment of patients with parkinson's disease. J. Clin. Invest. 2013, 123, 2730-2736.
56. Aviles-Olmos, I.; Dickson, J.; Kefalopoulou, Z.; Djamshidian, A.; Kahan, J.; Fmedsci, P.E.; Whitton, P.; Wyse, R.; Isaacs, T.; Lees, A.; et al. Motor and cognitive advantages persist 12 months after exenatide exposure in parkinson's disease. J. Parkinsons Dis. 2014, 4, 337-344.
57. Simuni, T.; Brundin, P. Is exenatide the next big thing in parkinson's disease? J. Parkinsons Dis. 2014, 4, 345-347.
58. Carta, A.R.; Simuni, T. Thiazolidinediones under preclinical and early clinical development for the treatment of parkinson's disease. Expert Opin. Investig. Drugs 2014, doi:10.1517/ 13543784.2015.963195.